This is a study to determine whether you can follow instructions at home. Yep it concludes that you are big boys and girls and can follow instructions to look after you own health. Well done. Well is it surprising as people have been taking medicines at home for along time. This study looks at ofatumumab which is delivered at home. There was a severe reaction so you have to be prepared.
Some places seem to have swapped people onto ofatmumab to get them away from the infusion requirements. Some places haven’t done this. Why are there big differences in infusion versus at home. Some places do not have infusion seat capacity. However, if you push treatments to home, will hospitals lose their infusion nurses and their capacity to do infusions.
Will NICE think if we start treating people at home then we dont need to pay staff to run the infusion units and we save 20% on Value Added Tax. If they are being poundland and making neuros use certain drugs over other drugs, will this come into their thinking. Will this be the way to go little and often at home or do you want the infrequent at hospital and forget about it?
Paling D, Cottrell D, Hamlin R, O’Leary C, Pearson O, Straukiene A, Kivi P, Rice W, Al-Azki S, Kondori N. Real-world evidence of clinical outcomes and adherence to ofatumumab in the UK and the impact of a patients support programme: A retrospective, non-interventional cohort study. Mult Scler Relat Disord. 2026 Jan 27;107:107030. doi: 10.1016/j.msard.2026.107030.
Background: Ofatumumab is the only anti-CD20 monoclonal antibody disease modifying therapy available for self- administration for adults with active relapsing remitting multiple sclerosis (RMS). This study aimed to investigate real-world adherence and clinical outcomes of ofatumumab-treated patients in the UK and looked at the impact of a patient support program called Kesimpta Connect (KC PSP) on these outcomes.
Methods: This retrospective observational cohort study examined adherence to ofatumumab in 155 RMS patients recruited from six UK MS centres. The primary objective of the study was to describe the medication possession ratio (MPR) adherence of ofatumumab treated patients over a 13-month period. The study also looked at clinical effectiveness measures, including change in annualized relapse rates (ARR). Safety and secondary-care use was also assessed in this study.
Results: 103 patients had data available to be assessed for adherence and clinical effectiveness. 87 % (n=90) of patients had an MPR adherence of 0.80 or greater and higher proportion of non-KC PSP users reported adherence of greater than 0.80 than KC PSP users (98.4 % vs 69.2 %). The total ARR decreased during the follow-up period from 0.33 (95 % CI 0.23-0.40) prior to ofatumumab initiation to 0.06 (95 % CI 0.01-0.11) 12-months after initiation. In terms of safety, 38.1 % (n=59/155) patients reported experiencing an adverse event during the follow-up period; one was reported to be severe. However, no patients reported discontinuing ofatumumab during the study follow-up period.
Conclusion: This study provides evidence of good adherence (i.e. can do better) for RMS patients using ofatumumab. Further, there is evidence of clinical effectiveness based on reduction in ARR post-ofatumumab initiation, as well as tolerability and a favourable safety profile. The results of this study support the continued use of ofatumumab in providing effective RMS disease management in the UK NHS.
Source: multiple-sclerosis-research.org